Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 145

1.

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Bakker M, Hoogkamer AQ, Boer JM, Hartman QJ, Stalpers F, Escherich G, de Haas V, de Groot-Kruseman HA, Pieters R, den Boer ML.

Sci Rep. 2018 Jan 12;8(1):693. doi: 10.1038/s41598-017-17704-4.

2.

Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Žaliová M, Sutton R, Öfverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Froňková E, Bakkus M, Tchinda J, Barbosa TDC, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grümayer R, Kuiper RP, den Boer ML, Cavé H, Moorman AV, Harrison CJ, Strehl S.

Blood Adv. 2017 Aug 14;1(19):1473-1477. doi: 10.1182/bloodadvances.2017006734. eCollection 2017 Aug 22.

3.

A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.

Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM.

Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30.

PMID:
29194562
4.

High PDGFRA expression does not serve as an effective therapeutic target in ERG-deleted B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Chatzivasileiou D, Hoogkamer AQ, Boer JM, Beverloo HB, Pieters R, den Boer ML.

Haematologica. 2018 Feb;103(2):e73-e77. doi: 10.3324/haematol.2017.171702. Epub 2017 Nov 23. No abstract available.

5.

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, van de Ven C, Koudijs MJ, Besselink NJM, de Groot-Kruseman HA, Zwaan CM, Horstmann MA, Pieters R, den Boer ML.

Oncotarget. 2017 Sep 16;8(52):89923-89938. doi: 10.18632/oncotarget.21027. eCollection 2017 Oct 27.

6.

Tunneling Nanotubes and Gap Junctions-Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions.

Ariazi J, Benowitz A, De Biasi V, Den Boer ML, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, Gousset K, Hanein D, Israel DI, Kimura S, Kirkpatrick RB, Kuhn N, Jeong C, Lou E, Mailliard R, Maio S, Okafo G, Osswald M, Pasquier J, Polak R, Pradel G, de Rooij B, Schaeffer P, Skeberdis VA, Smith IF, Tanveer A, Volkmann N, Wu Z, Zurzolo C.

Front Mol Neurosci. 2017 Oct 17;10:333. doi: 10.3389/fnmol.2017.00333. eCollection 2017. Review.

7.

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML.

Leukemia. 2018 Apr;32(4):931-940. doi: 10.1038/leu.2017.303. Epub 2017 Oct 3.

8.

BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.

Boer JM, den Boer ML.

Eur J Cancer. 2017 Sep;82:203-218. doi: 10.1016/j.ejca.2017.06.012. Epub 2017 Jul 12. Review.

PMID:
28709134
9.

Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.

de Rooij B, Polak R, van den Berk LCJ, Stalpers F, Pieters R, den Boer ML.

Haematologica. 2017 Oct;102(10):e389-e393. doi: 10.3324/haematol.2016.159517. Epub 2017 Jun 15. No abstract available.

10.

Tunneling nanotubes facilitate autophagosome transfer in the leukemic niche.

de Rooij B, Polak R, Stalpers F, Pieters R, den Boer ML.

Leukemia. 2017 Jul;31(7):1651-1654. doi: 10.1038/leu.2017.117. Epub 2017 Apr 12. No abstract available.

11.

Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.

Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, Roth M, Zuber J, Stanulla M, den Boer ML, Mullighan CG, Strehl S, Busslinger M.

EMBO J. 2017 Mar 15;36(6):718-735. doi: 10.15252/embj.201695495. Epub 2017 Feb 20.

12.

The unpredictable Northern light: The rise and fall of the aurora kinase inhibitors?

Zwaan CM, Den Boer ML.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26418. Epub 2017 Feb 16. No abstract available.

PMID:
28205329
13.

Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome.

Witkowski MT, Hu Y, Roberts KG, Boer JM, McKenzie MD, Liu GJ, Le Grice OD, Tremblay CS, Ghisi M, Willson TA, Horstmann MA, Aifantis I, Cimmino L, Frietze S, den Boer ML, Mullighan CG, Smyth GK, Dickins RA.

J Exp Med. 2017 Mar 6;214(3):773-791. doi: 10.1084/jem.20160048. Epub 2017 Feb 11.

14.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN.

Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

15.

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML.

Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.

16.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV.

Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26.

17.

Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.

van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, Cazzaniga G, Biondi A, den Boer ML, Pieters R, Stam RW.

Haematologica. 2016 Mar;101(3):e95-8. doi: 10.3324/haematol.2014.122119. Epub 2015 Dec 17. No abstract available.

18.

B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment.

Polak R, de Rooij B, Pieters R, den Boer ML.

Blood. 2015 Nov 19;126(21):2404-14. doi: 10.1182/blood-2015-03-634238. Epub 2015 Aug 21.

19.

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML.

Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23.

PMID:
26202931
20.

BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.

Boer JM, Marchante JR, Evans WE, Horstmann MA, Escherich G, Pieters R, Den Boer ML.

Haematologica. 2015 Sep;100(9):e354-7. doi: 10.3324/haematol.2015.124941. Epub 2015 Jun 4. No abstract available.

Supplemental Content

Loading ...
Support Center